Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KY-02327 是 KY-02061的一种类似物,具有代谢稳定性。KY-02327是Dishevelled (Dvl)-CXXC5相互作用抑制剂。KY-02327激活Wnt/β-catenin 途径,从而促进成骨细胞分化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,890 | 现货 | ||
5 mg | ¥ 3,990 | 现货 | ||
10 mg | ¥ 5,680 | 现货 | ||
25 mg | ¥ 8,750 | 现货 | ||
50 mg | ¥ 11,700 | 现货 | ||
100 mg | ¥ 15,900 | 现货 | ||
500 mg | ¥ 31,800 | 现货 |
产品描述 | KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation. |
体外活性 | KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner [1]. KY-02327 (1-10 μM) increases the mRNA levels of collagen 1a ( Col1a ) and osteocalcin ( OCN ) which are the osteoblast differentiation markers[1]. |
体内活性 | KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) successfully rescues bone loss in the ovariectomized (OVX) mouse model which is potential candidate for the development of bone anabolic anti-osteoporosis drug[1] . Animal Model: 8-week-old female BL6 mice (ovariectomized (OVX)-induced osteoporosis model mice) [1] Dosage: 20 mg/kg Administration: P.o.; administered for 5 sequential days per week for 4 weeks Result: Newly formed bones which labeled with calcein were decreased in the femur of vehicle‐treated OVX mice. |
分子量 | 373.45 |
分子式 | C20H27N3O4 |
CAS No. | 2093407-25-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (267.77 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6777 mL | 13.3887 mL | 26.7773 mL | 66.9434 mL |
5 mM | 0.5355 mL | 2.6777 mL | 5.3555 mL | 13.3887 mL | |
10 mM | 0.2678 mL | 1.3389 mL | 2.6777 mL | 6.6943 mL | |
20 mM | 0.1339 mL | 0.6694 mL | 1.3389 mL | 3.3472 mL | |
50 mM | 0.0536 mL | 0.2678 mL | 0.5355 mL | 1.3389 mL | |
100 mM | 0.0268 mL | 0.1339 mL | 0.2678 mL | 0.6694 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KY-02327 2093407-25-9 Others Wnt CXXC5 osteoblast differentiation inhibit KY 02327 anti-osteoporosis Dishevelled bone KY02327 Inhibitor anabolic inhibitor